FABP4 characterizes metabolic–immune interactions and serves as a prognostic biomarker across gynecologic malignancies: a multi-omics integrative analysis

Abstract

Highlights • FABP4 is broadly downregulated across five gynecologic malignancies.• Promoter hypermethylation is associated with reduced FABP4 expression.• High FABP4 marks poor ovarian/cervical but favorable endometrial outcomes.• Single-cell and spatial data link stromal FABP4 to metabolic–immune crosstalk.• FABP4 knockdown suppresses cervical cancer cell invasion and migration.